A genome wide CRISPR/Cas9 screen for activators of dendritic cells
Authors
L Boquete Vilarino1; L Escudero-Ibarz2; V Quarantotti2; D Ross-Thriepland2; P Kozik1; 1 MRC Laboratory of Molecular Biology, UK; 2 Discovery Sciences, R&D, AstraZeneca, Cambridge, UK, UK
Abstract
Tumour immunogenicity is defined as the ability of the
PDF supporting document